placeholder
MAJOR72
CLINICAL TRIALLimited grounding
Q&A: Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD - Patient Care Online
A cardiologist discussed how tirzepatide (a dual-action weight-loss and diabetes drug) performed better than dulaglutide (another diabetes drug) in protecting the heart and kidneys in a clinical study. The comparison highlights tirzepatide's broader benefits beyond weight loss.
Analysis
Cardiorenal edge over dulaglutide strengthens tirzepatide's case beyond weight loss, supporting Lilly's push to expand Mounjaro/Zepbound into outcomes-driven indications.
- Tirzepatide outperformed dulaglutide on cardiorenal outcomes in a clinical study
- Steven Nissen, MD discussed the comparison in a Q&A format
- Findings position tirzepatide's benefits beyond weight loss
Tirzepatide News12d
Read